难治性甲状腺癌免疫治疗进展  

Advances in immunotherapy for refractory thyroid carcinoma

作　　者：杜成成 高再荣[1] Du Chengcheng;Gao Zairong(Department of Nuclear Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Hubei Province Key Laboratory of Molecular Imaging,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院核医学科、分子影像湖北省重点实验室,武汉430022

出　　处：《中华核医学与分子影像杂志》2021年第8期496-500,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金(81771866)。

摘　　要：难治性甲状腺癌的预后差,是影响甲状腺癌患者生存的主要因素。目前临床上常用多激酶抑制剂、手术、粒子植入治疗等治疗方法,可在一定程度上改善患者的预后,但总体疗效仍不尽人意。近年来,免疫治疗在许多肿瘤的治疗中显现出较高的有效性、安全性和可靠性。该文对免疫治疗在难治性甲状腺癌治疗中的作用机制、现状、治疗方法、展望等方面进行了综述。The poor prognosis of refractory thyroid cancer is the critical factor affecting the survival of patients with thyroid cancer.At present,multi-kinase inhibitors,surgery,particle implantation and other therapeutic methods are commonly used in clinical practice,which can improve the prognosis of patients to some extent,but the overall efficacy is still unsatisfactory.In recent years,immunotherapy has shown high efficacy,safety and reliability in the treatment of many tumors.In this article,the mechanism,current situation,method and prospect of immunotherapy in patients with refractory thyroid cancer are presented.

关 键 词：甲状腺肿瘤 免疫疗法 发展趋势 

分 类 号：R736.1[医药卫生—肿瘤]